What Role will Ensifentrine Play in the Future Treatment of Chronic Obstructive Pulmonary Disease Patients? Implications from Recent Clinical Trials
- 2 October 2023
- journal article
- research article
- Published by Taylor & Francis in Immunotherapy
- Vol. 15 (18) , 1511-1519
Abstract
Data from the phase III ENHANCE clinical trials provide compelling evidence that ensifentrine, an inhaled ‘bifunctional’ dual phosphodiesterase 3/4 inhibitor, can provide additional benefit to exis... Plain language summary Chronic obstructive pulmonary disease (COPD) is the name for a group of lung conditions that cause breathing difficulties/airflow limitations. The airflow limitation is not c... Tweetable abstract Ensifentrine, an inhaled ‘bifunctional’ dual PDE3/4 inhibitor, can provide additional benefit to existing treatments in patients with COPD and represents a ‘first in class’ drug ...Keywords
Funding Information
- Verona Pharma (9717732, 9700558, 20160008363, 20160000790, 20170266190)
This publication has 30 references indexed in Scilit:
- Phosphodiesterase Inhibitors for the Treatment of Asthma and Chronic Obstructive Pulmonary DiseaseInternational Archives of Allergy and Immunology, 2014
- CFTR: cystic fibrosis and beyondEuropean Respiratory Journal, 2014
- DualPDE3/4 andPDE4 Inhibitors: Novel Treatments ForCOPDand Other Inflammatory Airway DiseasesBasic & Clinical Pharmacology & Toxicology, 2014
- Efficacy and safety of RPL554, a dual PDE3 and PDE4 inhibitor, in healthy volunteers and in patients with asthma or chronic obstructive pulmonary disease: findings from four clinical trialsThe Lancet Respiratory Medicine, 2013
- Cigarette smoke and CFTR: implications in the pathogenesis of COPDAmerican Journal of Physiology-Lung Cellular and Molecular Physiology, 2013
- Effect of the Mixed Phosphodiesterase 3/4 Inhibitor RPL554 on Human Isolated Bronchial Smooth Muscle ToneThe Journal of Pharmacology and Experimental Therapeutics, 2013
- The Pharmacology of Two Novel Long-Acting Phosphodiesterase 3/4 Inhibitors, RPL554 [9,10-Dimethoxy-2(2,4,6-trimethylphenylimino)-3-(N-carbamoyl-2-aminoethyl)-3,4,6,7-tetrahydro-2 H-pyrimido[6,1-a]isoquinolin-4-one] and RPL565 [6,7-Dihydro-2-(2,6-diisopropylphenoxy)-9,10-dimethoxy-4 H-pyrimido[6,1-a]isoquinolin-4-one]The Journal of Pharmacology and Experimental Therapeutics, 2006
- Phosphodiesterase 4D Forms a cAMP Diffusion Barrier at the Apical Membrane of the Airway EpitheliumJournal of Biological Chemistry, 2005
- Adenosine Receptors and Phosphodiesterase Inhibitors Stimulate Cl− Secretion in Calu-3 CellsAmerican Journal of Respiratory Cell and Molecular Biology, 2003
- The effect of selective and non‐selective phosphodiesterase inhibitors on allergen‐ and leukotriene C4‐induced contractions in passively sensitized human airwaysBritish Journal of Pharmacology, 2000